Financial Resources

Go to www.aaapatientconnect.com for more information about AAA PatientCONNECT™

AAA PatientCONNECT provides services to facilitate your access to LUTATHERA® (lutetium Lu 177 dotatate) treatment. This may include:

Patient Financial Assistance

  • Commercial patient copay assistance

Other Assistance

  • Insurance benefits verification
  • Prior authorization eligibility check
  • Financial assistance for eligible patients

Underinsured or Uninsured Financial Assistance

If a patient does not have insurance, is underinsured, has insurance yet still cannot afford, or otherwise cannot afford their LUTATHERA treatment there may be an option for them. All patients must enroll through AAAPC at www.aaapatientconnect.com or by calling 1-844-638-7222.

For more information, contact AAA PatientCONNECT™ at 1-844-638-7222.

Financial assistance for patients with commercial insurance

AAA PatientCONNECT™ may provide copay assistance for LUTATHERA treatment to patients who have commercial insurance and meet certain eligibility criteria.*

You may qualify for assistance if:

  • You have commercial insurance and certify that you do not have any government insurance
  • Your LUTATHERA treatment is being provided in an outpatient setting
  • You are a permanent resident of the United States, including any of its territories, or the District of Columbia

Copay assistance is not available through the AAA PatientCONNECT™ program for patients who have public or government insurance, such as insurance available as through Medicare, Department of Veterans Affairs, or the Department of Defense. AAA PatientCONNECT™ is not an insurance program and is not a substitute for medical insurance.

  • Eligibility restrictions may apply. For full terms and conditions, please call AAA PatientCONNECT™ at 1-844-638-7222. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the copayment support provided under this program, e.g. copay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payers of any benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law or restricted.

Enrolling in copay assistance

To enroll in financial assistance for commercial insurance, your healthcare provider must submit a completed and signed AAA PatientCONNECT Program Enrollment Form on your behalf. AAA PatientCONNECT Program Enrollment Forms are available online at  www.aaapatientconnect.com

By signing the AAA PatientCONNECT Program Enrollment Form, you agree that, if approved for the copay assistance program, all copay assistance funds distributed will be used only for the cost of LUTATHERA®.

Receiving copay financial assistance

Upon approval, AAA PatientCONNECT will send you an approval letter and outline of the copay assistance funds that are available for your treatment. Proof of LUTATHERA® treatment and claims processed must be submitted to AAA PatientCONNECT for distribution of copay assistance funds. Upon receipt of required documents, copay assistance funds will be processed.

For more information, contact AAA PatientCONNECT™ at 1-844-638-7222.

TERMS AND CONDITIONS

AAA PatientCONNECT™ -- LUTATHERA® COPAY ASSISTANCE PROGRAM

Limitations apply. The Advanced Accelerator Applications (AAA) PatientCONNECT™ Lutathera® Copay Assistance Program (the “Program”) is valid only for patients with commercial insurance coverage who are otherwise eligible for the Program. The Program is not valid under Medicare, Medicaid, or any other federal or state program, for cash-paying patients, where the product is not covered by the patient’s commercial insurance, or where the patient’s insurer reimburses the patient for the entire cost of Lutathera (lutetium Lu 177 dotatate). The patient is obligated to notify AAA PatientCONNECT™ at 844-638-7222 promptly if the patient’s insurance coverage changes or otherwise becomes ineligible for coverage under the Program. Patient must be age 18 or older. Patient must be a permanent resident of the United States, Commonwealth of Puerto Rico or the United States Virgin Islands. Patient must be prescribed Lutathera for an FDA approved indication. Treatment with Lutathera must be provided in an appropriate outpatient setting. The Program provides that an eligible patient will be responsible for the first $25.00 per infusion and then may receive up to a maximum of $15,000.00 over the course of the treatment (i.e., four Lutathera infusions) to cover eligible out-of-pocket costs for Lutathera. After the maximum coverage is reached, the patient will be responsible for any costs incurred. Patient must have an out-of-pocket cost for Lutathera and be administered Lutathera prior to the expiration date of the Program. The benefit available under the Program is valid for the patient’s out-of-pocket cost for Lutathera only. It is not valid for any other out-of-pocket costs (e.g., office visit charges or medication administration charges) even if such costs are associated with the administration of Lutathera. If a patient’s insurance benefit year expires during the course of approved Program eligibility, confirmation of ongoing treatments and updated insurance information must be received from the treatment facility or physician’s office for eligibility under the Program to be continued into the new benefit period. The patient is subject to eligibility verification prior to enrollment in the Program. The patient’s eligibility for the Program expires on the anniversary of the first year following the patient’s initial approval for the Program. Thereafter, the patient may re-enroll in the Program on a yearly basis. For each re-enrollment period, the patient is subject to eligibility verification. Reimbursement under the Program is processed after services are rendered and the appropriate documentation is submitted to the Program. Such documentation must be submitted within 365 days after the date of service and must specify a line item specifically for Lutathera. The benefit conferred by the Program is exclusively for the patient. The Program is not valid where prohibited by law. Patient and the patient’s health care provider must not seek reimbursement for the benefit conferred by the Program from any other party, including without limitation, any health insurance program or plan, flexible spending account or healthcare savings account. The Program is not health insurance. The Program may not be combined with any third-party rebate, coupon, or offer. Data related to the patient’s receipt of benefits under the Program may be collected, analyzed and shared with AAA, in an aggregated and patient de-identified form, for purposes that include assessing the Program and potentially making adjustments to such Program. Advanced Accelerator Applications, a Novartis company, reserves the right to rescind, revoke or amend the Program and/or discontinue assistance at any time without notice. No other purchase is necessary. Program is limited to 1 per person during this offering period and is not transferable.

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

home_logo
Patient Discussion Guide
You are now leaving the LUTATHERA.com website. Advanced Accelerator Applications USA, Inc. is not responsible for the content on external websites.